● In Stock
CJC-1295 DAC
≥99% Purity | HPLC Verified
$45.00
PASSED
Sterility & Endotoxins
PASSED
Net Content & Purity
Purity:
≥99%
Store at
-20°C
Long-acting GHRH analog with albumin-binding DAC modification studied for sustained growth hormone release. Research use only.
Research Use OnlyNot for human or veterinary use. For in vitro laboratory research only.
| Strength | 5mg |
| molecular_formula | C152H252N44O42 |
| Molecular Weight | 3367.97 g/mol |
| Purity | >99% (HPLC) |
| Form | Lyophilized Powder |
8 days
Plasma Half-Life
5.8–8.1 days via albumin binding
10×
GH Elevation
2–10× above baseline for 6+ days
28 days
IGF-1 Elevation
Maintained above baseline (multi-dose)
99%+
Purity Verified
HPLC tested, COA included
How CJC-1295 DAC Works
Three interlocking mechanisms convert a 7-minute peptide into an 8-day sustained GH stimulator
GHRH-R Agonist
GHRH Receptor Activation
CJC-1295 DAC is a 30-amino acid analog of GHRH(1–29) with four strategic substitutions that confer protease resistance. It binds and activates GHRH receptors on pituitary somatotrophs, directly stimulating growth hormone synthesis and pulsatile release — the same signaling axis as endogenous GHRH, but massively extended.
- Selective GHRH receptor agonism
- Stimulates GH synthesis in somatotrophs
- Preserves pulsatile GH secretion pattern
DAC Technology
Albumin Binding — Half-Life Extension
The Drug Affinity Complex (DAC) is a maleimidopropionic acid group attached to Lys8 of the peptide. After injection, it covalently bonds to Cys34 of circulating serum albumin — eliminating DPP-IV cleavage and extending half-life from 7 minutes to 5.8–8.1 days. The albumin acts as a circulating depot, slowly releasing active peptide.
- Covalent bond to serum albumin Cys34
- Eliminates DPP-IV protease cleavage
- 1,650× longer half-life vs native GHRH
IGF-1 Axis
Downstream IGF-1 Elevation
Sustained GH elevation drives hepatic insulin-like growth factor-1 (IGF-1) production. IGF-1 mediates downstream effects and remains elevated 9–11 days from a single injection due to the sustained GH signal, with cumulative elevation demonstrated on multi-dose protocols.
- IGF-1 elevated 1.5–3× above baseline
- Sustained 9–11 days from single injection
- 28-day elevation on multi-dose protocol
What Research Has Shown
Key findings from two randomized, placebo-controlled clinical trials — 57 healthy adults — Teichman et al. JCEM 2006
⚠️ RESEARCH NOTE
Phase 1/2 data from 57 healthy adults (Teichman et al. JCEM 2006) is available. CJC-1295 DAC is not FDA-approved. Phase 3 development was not pursued after developer ConjuChem dissolved. Data should not be extrapolated to therapeutic use.
Research Applications
Primary areas of GH/IGF-1 axis investigation from clinical and preclinical data
GH / IGF-1 Axis
Sustained GH Stimulation
Single SC injection elevates GH 2–10× for 6+ days. Multi-dose protocols maintain IGF-1 above baseline for 28 days in healthy adults.
Pharmacokinetics
Albumin-Depot Mechanism
DAC covalently binds serum albumin Cys34, creating an endogenous depot. Half-life measured at 5.8–8.1 days — enabling once-weekly administration in research protocols.
Endocrinology
GHRH Axis Selectivity
Cortisol, thyroid hormones, and prolactin remain unaffected across all doses tested — confirming selective GHRH receptor agonism without hypothalamic–pituitary–adrenal axis activation.
Animal Models
Growth Normalization
Once-daily CJC-1295 normalized growth in GHRH knockout mice, demonstrating in vivo GHRH receptor replacement activity with favorable tolerability in rodent models.
Safety Profile from Research
Clinical trial safety data — 57 subjects, 28–49 day observation windows (Teichman et al. JCEM 2006)
✓Zero serious adverse events reported across both randomized, placebo-controlled trials.
✓Cortisol, thyroid hormones (T3/T4/TSH), and prolactin remained unaffected at all doses tested — confirming selective GHRH-R agonism.
✓Only mild, transient side effects reported: injection site reactions and dose-dependent water retention in a subset of subjects.
✓Dose-response relationship confirmed — 30–60 µg/kg SC produced predictable, proportional GH and IGF-1 responses.
⚠️ CJC-1295 DAC is not FDA-approved. Phase 3 development was not completed. For in vitro research use only — not for human therapeutic use.
Compound Information
Technical specifications for CJC-1295 DAC (DAC:GRF)
| Also Known As | DAC:GRF, CJC-1295 with DAC |
| Type | Synthetic GHRH analog with Drug Affinity Complex |
| CAS Number | 863288-34-0 |
| Molecular Weight | 3,647.1 g/mol |
| Amino Acids | 30 (GHRH 1–29 analog) |
| DAC Modification | Maleimidopropionic acid on Lys8 → covalent albumin Cys34 binding |
| Plasma Half-Life | 5.8–8.1 days (albumin-bound) |
| Form | Lyophilized powder |
| Purity | ≥99% (HPLC verified) |
| Testing | Third-party HPLC, Mass Spec, Endotoxin |
| Storage (lyophilized) | -20°C for up to 24 months |
| Storage (reconstituted) | 2–8°C, use within 28 days |
| Solubility | Bacteriostatic water for reconstitution |
| COA | Included with every order |
Frequently Asked Questions
Common questions about CJC-1295 DAC research
CJC-1295 DAC (also called DAC:GRF) is a 30-amino acid synthetic analog of growth hormone-releasing hormone (GHRH) with a Drug Affinity Complex (DAC) modification — a maleimidopropionic acid group at Lys8. After injection, this group covalently bonds to Cys34 of circulating serum albumin. Albumin acts as a circulating depot, slowly releasing active peptide and extending the half-life from ~7 minutes (native GHRH) to 5.8–8.1 days.
Teichman et al. (JCEM 2006) conducted two randomized, double-blind, placebo-controlled trials in 57 healthy adults (ages 21–61). Results: a single 30–60 µg/kg SC injection elevated GH 2–10× above baseline for 6+ days and IGF-1 by 1.5–3× for 9–11 days. Multi-dose protocols (2–3 weekly/biweekly injections) maintained IGF-1 above baseline for up to 28 days with a cumulative effect. No serious adverse events were reported.
The sole structural difference is the DAC modification. CJC-1295 without DAC (Modified GRF 1-29, "Mod GRF") has a half-life of approximately 20–30 minutes and must be administered multiple times daily for sustained GH stimulation. CJC-1295 DAC's albumin binding extends the half-life to ~8 days — enabling once-weekly dosing while preserving the same GHRH receptor selectivity.
No. CJC-1295 DAC acts selectively on the GHRH receptor on pituitary somatotrophs. Clinical trial data confirmed that cortisol, thyroid hormones (T3, T4, TSH), and prolactin were unaffected across all doses tested. This selectivity distinguishes it from non-selective GH secretagogues such as GHRP-6 and hexarelin, which elevate cortisol and prolactin as known side effects.
No. CJC-1295 DAC was developed by ConjuChem Biotechnologies (Canada). Phase 1/2 trials were completed in 2006, but Phase 3 development was never pursued after the company dissolved. It has never received FDA approval and is classified as a research compound. It is sold for in vitro research purposes only and is not intended for human therapeutic use.
Lyophilized (powder) form should be stored at -20°C for up to 24 months. Once reconstituted with bacteriostatic water, store at 2–8°C and use within 28 days. Avoid repeated freeze-thaw cycles and protect from light and heat. The DAC modification does not significantly affect peptide stability in lyophilized form.
Sources & References
PubMed
Prolonged stimulation of GH and IGF-I secretion by CJC-1295, a long-acting analog of GHRH, in healthy adults
2006
PubMed
Once-daily administration of CJC-1295 normalizes growth in the GHRH knockout mouse
2006
PubMed
Drug Affinity Complex technology: extending peptide half-life via covalent albumin binding
2000
PubMed
GHRH analog sermorelin and CJC-1295 pharmacodynamic comparison in GH deficiency models
2003
⚠️ For research use only. Not for human or veterinary therapeutic use. These statements have not been evaluated by the Food and Drug Administration.
Published research on this compound is available through PubMed and other scientific databases.
Certificate of Analysis
| Analysis Date: | Available on request |
| Lot Number: | Batch-specific |
| Purity: | >99% (HPLC) |
Third-Party Testing
- ✓ Identity verification (Mass Spectrometry)
- ✓ Purity analysis (HPLC)
- ✓ Sterility testing
- ✓ Endotoxin screening
Storage Conditions
- Lyophilized: Store at -20°C, protected from light
- Reconstituted: Store at 2-8°C, use within 30 days
- Stability: 24 months from manufacture date when stored properly
Handling Guidelines
- Use sterile technique when reconstituting
- Allow vial to reach room temperature before opening
- Reconstitute with bacteriostatic water or sterile saline
- Avoid repeated freeze-thaw cycles
RESEARCH INSIGHTS
3D Structure
CJC-1295 DAC
This compound has been extensively studied in peer-reviewed literature. Eon Peptides provides this product exclusively for legitimate in-vitro research and analytical applications.
- • High-purity research compound
- • Full analytical documentation included
- • Third-party verification available
PRODUCT SPECIFICATIONS
LOT DATA
| Lot Number | Assigned on shipment |
| Verified Purity | >99% |
| Quantity | 5mg |
MOLECULAR DATA
| Molecular Formula | Available on request |
| Form | Lyophilized Powder |
| Appearance | White to off-white powder |
Researchers who studied this also studied...
Related products
-
Price range: $40.00 through $55.00 Select options This product has multiple variants. The options may be chosen on the product page
